Because Social Media increases Awareness and brings the DES Community Together
Extrait d’un journal de bord d’une femme numérique, juin 2017
“Il faut de tout pour faire un monde”,
… et …
“à toute chose malheur est bon”.
dit on… voici un témoignage, d’une fille distilbène, qui sort de l’ordinaire…
Both male and female children born to women exposed to chemotherapy have fewer children
Background
There is little known about the transgenerational effect of chemotherapy. For example, chemotherapy is known to decrease fecundity in women. But if women are able to have offspring after chemotherapy exposure, do these children also have decreased fecundity?
Methods
This study is a retrospective cohort study utilizing the Utah Population Database (UPDB), a comprehensive resource that links birth, medical, death and cancer records for individuals in the state of Utah. The male and female children (F1 generation) of chemotherapy-exposed women (F0 generation) were identified. The number of live births (F2 generation) to this F1 generation was compared to two sets of chemotherapy-unexposed, matched controls using conditional Poisson regression models (regression coefficient, 95% confidence interval, P-value). The first unexposed was established using the general population and the second unexposed was established using first cousins to the F1 generation.
Results
The exposed F1 individuals had 77.2% fewer children (−1.48; −2.51 to −0.70; p = 0.001) relative to the unexposed general population. F1 males had 86.9% fewer children (−2.03; −4.91 to −0.51; p = 0.005) and F1 females had 70.5% fewer children (−1.22; −2.40 to −0.36; p = 0.016). When comparing to their unexposed cousins, the F1 generation (both sexes combined) had 74.3% (−1.36; −2.82 to −0.29; p = 0.029) fewer children.
Conclusion
The sons and daughters (F1 generation) of chemotherapy-exposed women have fewer live births when compared to both matched, unexposed general population and cousin controls. Chemotherapy may have a transgenerational effect in exposed women which needs further investigation.
À la recherche des contrées spermatiques
Parfois les chiffres s’expriment d’eux-mêmes sans qu’il soit nécessaire de les faire parler. En 1940, la quantité de spermatozoïdes par ml de sperme était de 113 millions. Cinquante ans plus tard, en 1990, elle était de 66 millions. Pendant la même période, le volume de l’éjaculat est passé de 3.40 ml à 2.75 ml.
Alors qu’un degré de réchauffement climatique fait l’objet d’un catastrophisme rabâché sur tous les médias, cet effondrement de la spermatogénèse se déroule dans le plus grand silence. Ce déficit de vulgarisation de la biologie et de la médecine, comparées à toutes les autres sciences dures ou molles, est un problème chronique qui provient essentiellement de la manipulation des normes.
Ainsi, devant cette catastrophe spermatique, l’OMS a tout simplement modifié les normes de l’hypospermie (limite à partir de laquelle on considère le sperme comme insuffisant). Surprenante manipulation. Pour l’éjaculat, cette norme était 3ml en 1940, 2ml en 1999 et 1,5 ml en 2010. Pour le taux de spermatozoïdes par ml, on a vite oublié les 66 millions de 1990, pour tomber rapidement à 20 millions en 1999 et à 15 en 2010 ! On a même décrété que la fertilité pouvait subsister jusqu’à 5 millions, sans considérer qu’un spermatozoïde victorieux qui pénètre un ovule du XXI° siècle a combattu vingt fois moins d’adversaires qu’en 1940.
Nous savons depuis longtemps que les multiples perturbateurs endocriniens de l’agro-alimentaire et de la pétrochimie sont à l’origine de cette dégénérescence spermatique, et nous savons depuis peu que les marques épigénétiques de ce processus sont héritables.
On peut expliquer le silence autour de ces faits de deux façons, l’une réfléchie, l’autre primesautière.
Les spermatozoïdes deviennent encore plus rares et plus fragiles que les abeilles et le dogme de la croissance du PIB est intouchable. Après avoir sauvé plusieurs industries en abaissant les normes de la spermatogenèse, la docile OMS a également favorisé l’industrie pharmaceutique en abaissant les normes de la glycémie et de la tension artérielle.
Devant l’impossible vulgarisation des sciences biomédicales, il ne nous reste plus qu’à espérer qu’il subsistera des contrées spermatiques où nos filles pourront aller se faire féconder…
Major depression, antidepressant use, and male and female fertility : Cohort study
Objective
To determine if maternal major depression (MD), antidepressant use, or paternal MD are associated with pregnancy outcomes after non-IVF fertility treatments.
Design
Cohort study, DOI: https://doi.org/10.1016/j.fertnstert.2018.01.029, May 2018.
Setting
Clinics.
Patient(s)
Participants in two randomized trials: PPCOS II (clomiphene citrate versus letrozole for polycystic ovary syndrome), and AMIGOS (gonadotropins versus clomiphene citrate versus letrozole for unexplained infertility).
Intervention(s)
Female and male partners completed the Patient Health Questionnaire (PHQ-9). Female medication use was collected. PHQ-9 score ≥10 was used to define currently active MD.
Main Outcome Measure(s)
Primary outcome: live birth. Secondary outcomes: pregnancy, first-trimester miscarriage. Poisson regression models were used to determine relative risks after adjusting for age, race, income, months trying to conceive, smoking, and study (PPCOS II versus AMIGOS).
Result(s)
Data for 1,650 women and 1,608 men were included. Among women not using an antidepressant, the presence of currently active MD was not associated with poorer fertility outcomes (live birth, miscarriage), but rather was associated with a slightly increased likelihood of pregnancy. Maternal antidepressant use (n = 90) was associated with increased risk of miscarriage, and male partners with currently active MD were less likely to achieve conception.
Conclusion(s)
Currently active MD in the female partner does not negatively affect non-IVF treatment outcomes; however, currently active MD in the male partner may lower the likelihood of pregnancy. Maternal antidepressant use is associated with first-trimester pregnancy loss, which may depend upon the type of antidepressant.
Swept under the rug: new report reveals toxics in European carpets threatening health, environment and circular economy
A new study identifies over 59 hazardous substances found in carpets sold in the EU, including endocrine disruptors and carcinogens, linked to serious health conditions such as cancers, learning disabilities and fertility problems. Exposure to these toxics via inhalation, ingestion and dermal contact proves extremely harmful to pregnant women, babies and small children who are particularly vulnerable to the effects of exposure to chemicals, as well as workers in the carpet industry who are exposed to those chemicals because of inadequate safety measures. Many of these toxic chemicals are also persistent polluters that stay in the environment and can cause adverse impacts on ecosystems. In some cases, health and environmental impacts only show decades later.
Hazardous toxics in carpets also pose additional obstacles to the recycling process, impacting the quality of the recycled end material and the cost-effectiveness of recycling. Less stringent regulations for recycled materials can lead to now-restricted chemicals persisting in recycled products and consequently harm health. In addition, at least 37 toxic substances have not been restricted and/or banned for use in carpets. Many of these have not even been fully evaluated for their health and environmental impacts. 10 substances are currently identified by the EU as Substances of Very High Concern (SVHC), of which only 4 are banned from the market.
The report contains a series of clear recommendations to the EU, Member States and manufacturers aimed at adopting a health-first approach towards the circular economy. It recommends protecting the environment and the health of European citizens by eliminating toxic substances, strengthening regulations for new products, consistent and faster chemicals regulation as well as producer responsibility and eco-design measures to ensure toxic-free carpets.
Prenatal exposure to consumer product chemical may affect male fertility in future generations
Chicago, IL – Chemicals found in a variety of routinely used consumer products may be contributing to the substantial drop in sperm counts and sperm quality among men in recent decades, a new study in mice suggests.
The study found the effect of chemicals that disrupt the body’s hormones, called endocrine-disrupting chemicals, may extend beyond more than one generation. The research results was presented Monday, March 19, at ENDO 2018, the 100th annual meeting of the Endocrine Society, in Chicago, Ill.
“Sperm counts among men have dropped substantially over the last few decades, but the reason for such an alarming phenomenon is not known. These results suggest that when a mother is exposed to an endocrine disruptor during pregnancy, her son and the son’s future generations may suffer from decreased fertility or hormone insufficiency,”
said lead author Radwa Barakat, B.V.S.C., M.Sc., of the College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Ill.
The researchers studied the effect of di-(2-ethylhexyl) phthalate (DEHP), which is among the most widely used endocrine-disrupting chemicals. It is found in a wide array of industrial and consumer products, including polyvinyl chloride (PVC) piping and tubing, cosmetics, medical devices and plastic toys. The study found that male mice exposed to DEHP prenatally had significantly less testosterone in their blood and fewer sperm in their semen. Consequently, they lost fertility at an age when they normally would have been fertile.
“Most surprisingly, the male mice born to male mice that were exposed to DEHP also exhibited similar reproductive abnormalities—indicating prenatal exposure to DEHP can affect the fertility and reproductive capacity of more than one generation of offspring,” “Therefore, DEHP may be a contributing factor to the decreased sperm counts and qualities in modern men compared to previous generations.”
Barakat said.
Barakat and colleagues gave pregnant mice one of four doses of DEHP, or a type of corn oil, from 11 days after they conceived until birth.
Adult males born to these mice were bred with unexposed female mice, to produce a second generation of mice. Young adult males from this second generation were bred with unexposed females to produce a third generation. When each generation of mice was 15 months old, the researchers measured sex hormone levels, sperm concentrations and sperm motility, or movement (a potential sign of infertility).
In second-generation males, only those descended from mice in the highest DEHP exposure group had abnormal reproductive results—lower testosterone concentration, sperms levels and sperm motility. Third-generation males descended from DEHP-exposed mice also exhibited reproductive abnormalities at age 15 months, even those descended from mice that received a lower dose of the chemical. The researchers were surprised to find that the lowest DEHP dose group exhibited the greatest abnormalities.
“This study underscores the importance of educating public to try their best effort to reduce their exposure to this chemical and also the need to substitute this chemical with a safer one,”
Barakat said.
More bad news for sperm…
Phthalate diesters, including di-(2-ethylhexyl) phthalate (DEHP) and diethyl phthalate (DEP), are chemicals to which humans are ubiquitously exposed. Humans are exposed simultaneously to multiple environmental chemicals, including DEHP and DEP. There is little information available about how each chemical may interact to each other if they were exposed at same time. The present study investigated effects of the combinational exposure of rats to DEP and DEHP on fetal Leydig cell development. The results showed that the gestational (GD12-20) exposure of DEP + DEHP resulted in synergistic and/or dose-additive effects on the development of fetal Leydig cell. The lowest observed adverse-effect levels (LOAEL) for fetal Leydig cell (aggregation and cell size), and StAR expressions were of 10 mg/kg and, lower than when these chemicals were exposed alone. Also, mathematical modeling the response curves supports the dose-addition model over integrated-addition model. Overall, these data demonstrate that individual phthalate with a similar mechanism of action can elicit cumulative, dose additive, and sometimes synergistic, effects on the development of male reproductive system when administered as a mixture.
Dr. Vliet offers a different perspective on hormones
This landmark work in women’s health identifies and offers solutions to the hormonal dysfunctions afflicting millions of young women, teens, and even children, that rob women of future fertility and contribute to devastating problems — from early onset puberty and obesity to depression and increased cancer risk. Women’s health is more than breast cancer, pregnancy, and menopause. In this groundbreaking new work, Dr. Elizabeth Lee Vliet identifies and explains rarely acknowledged, pervasive threats to young women’s health and fertility — PCOS (Polycystic Ovary Syndrome), POD (Premature Ovarian Decline), and Premature Ovarian Failure (menopause in the young) — and the overlooked causes of endometriosis, cystitis, early puberty, allergies, heart disease, mood disorders, depression, chronic fatigue, fibromyalgia, bone loss, anxiety, obesity, and diabetes.
A kind of “Silent Spring” of women’s health, “It’s My Ovaries, Stupid!” presents compelling evidence from worldwide research that common environmental toxins and endocrine disruptors in pesticides, plastic food wrappers, food additives, preservatives, soy supplements, aspartame in diet sodas and junk food, and more — as well as lifestyle factors such as stress — can all profoundly disrupt hormone function, even in childhood.Insidious robbers of quality of life, fertility, and health, hormone dysfunctions are on the rise today, afflicting younger and younger women.Why? What can you do about it? How can you get tested? What treatments are available? Dr. Vliet interprets the latest scientific research and draws on more than twenty years of clinical experience to answer these and many other crucial questions about commonhealth problems in young women.Whose job is it to take care of the ovaries…beyond their function in reproduction? Why do you have trouble getting help for “hormone problems” that are clearly linked to your monthly cycle?
“It’s My Ovaries, Stupid!” bridges this gap in women’s health care and shows you how to understand your symptoms and get reliable tests, how to receive treatment and improve your health, how to wade through the controversies surrounding hormone replacement therapy, and how to explore cutting-edge options for thyroid problems.You can’t afford “not” to read this book. Your life, your fertility, and your long-term health may depend on it. It’s not all in your head, and it’s not just stress. It’s your ovaries!
Infertility Linked to Higher Risk of Death Among Women
Scientists have previously linked infertility in men to a heightened risk of premature death. Now, a new study also has a similar association among women.
According to researchers, women with fertility problems have a 10% increased risk of dying earlier than their counterparts – as well as a 20% increased risk of cancer-fertelated mortality, 44% increased risk of dying of breast cancer, 70% increased risk of dying of diabetes…
“Is it infertility itself or an underlying condition that predisposes an individual to infertility that drives these increased risks?”
asks study lead author Natalie Stentz, MD, a fellow in Reproductive Endocrinology and Infertility at the Perelman School of Medicine at the University of Pennsylvania.
Professeur Michel Tournaire, Réseau DES France, Forum d’Infertilité 2017
Vidéos en français: Distilbène DES : 60 vidéos à visionner sur YouTube.
Le troisième génération de victimes du médicament Distilbène® arrive aujourd’hui en âge de procréer.
Qu’en est-il au niveau de leur fertilité et risques supplémentaires en cas de grossesse ?
Le Professeur Michel Tournaire, membre du Conseil Scientifique de Réseau DES France, présente de nouveaux résultats de l’étude Distilbène 3 générations :
Enregistrement provenant de la 4ème Journée Nationale de l’Infertilité, un forum d’information et d’aide aux personnes infertiles organisé cet automne 2017, Paris 12.
